The aim of the study was to investigate the changes in the thyroid axis setpoint after long-term suppressive levothyroxine therapy for differentiated thyroid carcinoma and the resulting changes in levothyroxine requirement. Ninety-nine differentiated thyroid cancer patients were reviewed. All patients had at least one known TSH-level≥0.01 mU/l (lower detection limit) and <1.0 mU/l within 2 years of initial treatment (time 1) and had at least one TSH-value≥0.01 mU/l and <1.0 mU/l after continuous LT4 therapy for a minimum of 5 years (time 2). At time 2 the mean LT4 dosage/kg body weight, TSH, FT3, and FT4 levels were significantly lower than at time 1, while body weight was higher. At time 2, the FT3/FT4 ratio rate had dropped significantly (p<0.001). At time 1, patients would require 2.96 μg/kg body weight to reach total TSH suppression. The dose of levothyroxine/kg required for suppression can be lowered by about 0.05 μg/kg body weight for each year of suppressive therapy. After a median of 12.7 years of continuous suppressive levothyroxine therapy, patients would require 2.25 μg/kg body weight (-23.5%) to reach total TSH-suppression. At least part of this reduction was independent of aging. As a result of changes in thyroid hormone metabolism and thyroid axis setpoint, long-term TSH-suppressive therapy contributes to a reduction in the dosage of levothyroxine per kilogram body weight required for full TSH suppression over time.

levothyroxine, pituitary, thyroid cancer, TSH suppression
dx.doi.org/10.1055/s-0034-1375678, hdl.handle.net/1765/67130
Hormone and Metabolic Research
Department of Internal Medicine

Verburg, F.A, Mäder, U, Grelle, I, Visser, T.J, Peeters, R.P, Smit, J.W.A, & Reiners, C. (2014). The Thyroid Axis 'Setpoints' are Significantly Altered After Long-Term Suppressive LT4 Therapy. Hormone and Metabolic Research, 46(11), 794–799. doi:10.1055/s-0034-1375678